Member Content

Is the Price Right for COVID-19 Treatment Remdesivir?

July 7, 2020

Since the first studies emerged suggesting Gilead Sciences, Inc.’s remdesivir was a promising treatment for COVID-19, speculation has abounded regarding what price the manufacturer would set for the antiviral drug. On June 29, Gilead ended that speculation by revealing that it will charge $2,340 for a typical five-day, six-vial treatment course for people covered by U.S. government health programs and $3,120 for those covered by private insurance.

Remdesivir has not been approved by the FDA, but the agency did grant the infused drug an Emergency Use Authorization for the treatment of hospitalized patients with severe COVID-19. It is being studied in multiple international trials; one U.S.-government led study found remdesivir shortened COVID-19 patients’ recovery time by 31%.

To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.

Payers Are Poised to See Changes From Hospital Transparency

July 6, 2020

In another blow to an industry already beleaguered by the COVID-19 pandemic, a federal judge recently upheld a federal rule that requires hospitals to engage in unprecedented price transparency measures. Health systems are likely preparing to comply with the new requirements even as they await the outcome of an appeal — but health insurers, too, are poised to feel an impact if the regulations go into effect.

To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.

House Committee Paints Damning Picture of Short-Term Plans

July 6, 2020

More than a year after they began probing health insurers and brokers for information to fuel an investigation of short-term, limited-duration insurance (STLDI) plans, Democratic leaders of the House Energy & Commerce Committee released a report concluding that this market’s growth has come at the expense of consumers who are often duped into purchasing bare-bones coverage.

Policy experts, however, disagree about what conclusions can actually be drawn from the latest salvo in an ongoing debate over alternatives to Affordable Care Act (ACA) exchange plans.

To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.

Cigna Taps Priority Health, Oscar to Bolster Offerings

July 6, 2020

Cigna Corp. has now partnered with two smaller insurers, Priority Health in Grand Rapids, Mich., and New York-based Oscar, in an effort to increase its share of commercial group business, particularly small groups.

The alliances, which take effect next year and later this year, respectively, widen available offerings for both Cigna and its partners: Cigna gets access to stronger provider networks and more advanced online tools than it has in-house, while Priority Health and Oscar get access to Cigna’s national platform.

To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.

Blues Plans Dominate Marketplaces; Medicaid Plans Increase Presence

July 6, 2020

by Jinghong Chen Between 2016 and 2018, Medicaid-focused insurers expanded their footprint into the Affordable Care Act (ACA) marketplaces by offering lower premiums for silver plans, according to a recent analysis by the Robert Wood Johnson Foundation. Blue Cross Blue Shield plans remained the dominant players, accounting for almost half of marketplace enrollment nationally in […]

To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.